A one year experience: T cell responses and viral replication in children with advanced human immunodeficiency virus type 1 disease treated with combination therapy including ritonavir

Pediatric Infectious Disease Journal

Volumn 18, Issue 7, 1999, Pages 650-652

  Pelton, Stephen I ^a   Johnson, Daniel ^c   Chadwick, Ellen ^b   Baldwin, Zachary ^c   Yogev, Ram ^b  

^a BOSTON MEDICAL CENTER   (United States)

^b CHILDREN'S MEMORIAL HOSPITAL   (United States)

^c UNIVERSITY OF CHICAGO   (United States)

Author keywords

Human immunodeficiency virus type 1; Immune reconstitution; Protease inhibitors; Ritonavir

Indexed keywords

LAMIVUDINE; PROTEINASE INHIBITOR; RITONAVIR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ADOLESCENT; ARTICLE; CELLULAR IMMUNITY; CHILD; CLINICAL ARTICLE; DNA DETERMINATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; LEUKOCYTE COUNT; LYMPHOCYTE COUNT; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TREATMENT OUTCOME; VIRUS REPLICATION;

ADOLESCENT; ANTI-HIV AGENTS; CD4 LYMPHOCYTE COUNT; CD4-CD8 RATIO; CD8-POSITIVE T-LYMPHOCYTES; CHILD; CHILD, PRESCHOOL; DRUG THERAPY, COMBINATION; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INFANT; LYMPHOCYTE COUNT; REVERSE TRANSCRIPTASE INHIBITORS; RITONAVIR; VIRUS REPLICATION;

EID: 0032770855     PISSN: 08913668     EISSN: None     Source Type: Journal    
DOI: 10.1097/00006454-199907000-00019     Document Type: Article

References (11)

1. Hammer SM, Squires KE, Hughes MD, et al. A controlled trial of two nucleoside analogues plus indinavir in persons with human immunodeficiency virus infection and CD4 cell counts of 200 per cubic millimeter or less. N Engl J Med 1998;337:725-33.
2. Cameron B, Heath-Chiozzi M, Kravcik S, et al. Prolongation of life and prevention of AIDS in advanced HIV immunodeficiency with ritonavir [Abstract LB6a]. In: Program and abstracts of the Third Conference on Retroviruses and Opportunistic Infections, Washington, DC, January 28 to February 1, 1996.
3. Cameron DW, Heath-Chiozz M, Danner S, et al. Randomized placebo-controlled trial of ritonavir in advanced HIV-1 disease: The Advanced HIV Disease Ritonavir Study Group. Lancet 1998;351:543-9.
4. Centers for Disease Control and Prevention. Guidelines for the use of antiretroviral agents in pediatric patients. MMWR 1998;47(RR-4):1-44.
5. Melvin AJ, Mohan KM, Manns Arcuino LA, Edelstein RE, Frenkel LM. Clinical, virologic and immunologic responses of children with advanced human immunodeficiency virus type 1 disease treated with protease inhibitors. Pediatr Infect Dis J 1997;16:968-74.
6. Jankelevich S, Mueller B, Smith S, et al. Long-term activity of indinavir/ZDV/3TC in HIV-1 infected children: results of a Phase I/II study [Abstract 231]. Presented at the Fifth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, February 1 to 5, 1998.
7. Yogev R, Stanley K, Nachman SA, et al. Virologie efficacy of ZDV + 3TC vs. d4T + ritonavir vs. 3TC + ZDV + ritonavir in stable antiretroviral experienced children (PACTG Trial 338) [Abstract LB-6]. Proceedings of the 37th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, September 28 to October 1, 1997. Washington, DC: American Society for Microbiology, 1997.
8. + lymphocyte counts predict both responses to antiretroviral therapy and therapeutic failure (VA Cooperative Study Group on AIDS). Ann Intern Med 1997;126:983-5.
9. Mofenson, LM, Korelitz J, Meyer WA III, et al. The relationship between serum human immunodeficiency virus type 1 (HIV-1) RNA level, CD4 lymphocyte percent, and long-term mortality risk in HIV-1 infected children. J Infect Dis 1997; 175:1029-38.
10. Stoddart C, Mammano F, Moreno M, et al. Lack of fitness of protease inhibitor-resistant HIV-1 in vivo [Abstract 4]. Presented at the Sixth Conference on Retroviruses and Opportunistic Infections, Chicago, IL, January 31 to February 4, 1999.
11. Kaufman D, Pantaleo G, Sudre P et al. CD4-cell count in HIV-1 infected individuals remaining viremic with highly active antiretroviral therapy (HAART): Swiss HIV Cohort Study [Letter]. Lancet 1998;351:723-4.